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Summary
Over the last decade there has been an explosion in complement thera-
pies; one-third of the drugs in the clinic or in development target C5 pro-
tein. Eculizumab, a monoclonal antibody (mAb) that binds C5 and blocks
its cleavage by the convertase, is the current reference standard treatment
for atypical haemolytic uraemic syndrome (aHUS) and paroxysmal noc-
turnal haemoglobinuria (PNH) and in clinical trials for many other dis-
eases. Here we describe a panel of novel anti-C5 mAb, including mAb
that, like Eculizumab, are efficient inhibitors of complement but, unlike
Eculizumab, inhibit across species, including human, rat, rabbit and gui-
nea pig. Several inhibitory anti-C5 mAb were identified and characterized
for C5 binding and lytic inhibitory capacity in comparison to current
therapeutic anti-C5 mAb; three clones, 4G2, 7D4 and 10B6, were selected
and further characterized for ligand specificity and affinity and cross-spe-
cies inhibitory activity. The mAb 10B6 was human-specific whereas mAb
4G2 and 7D4 efficiently inhibited lysis by human, rabbit and rat serum,
and weakly inhibited guinea pig complement; 7D4 also weakly inhibited
mouse complement in vitro The rat C5-cross-reactive mAb 4G2, when
administered intraperitoneally in a rat model of myasthenia gravis, effec-
tively blocked the disease and protected muscle endplates from destruc-
tion. To our knowledge this is the first report of an anti-C5 function
blocking mAb that permits preclinical studies in rats.
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Introduction
The complement system is a central component of innate
immunity responsible for recognition and killing of bacte-
ria and promotion of phagocytosis through opsonization.
The system evolved to protect from pathogens; however,
recent reports have highlighted other homeostatic roles of
complement, including as a driver of inflammation, mod-
ulator of adaptive immunity and metabolism, and archi-
tect of neural development.1–3 Dysregulation of
complement leads to pathology, important in a large
number of inflammatory and degenerative diseases.4
Genome-wide association studies have provided support-
ing evidence that complement is involved in many com-
mon diseases.5–8 Complement can be the main cause of
the disease, for example in paroxysmal nocturnal
haemoglobinuria (PNH) and atypical haemolytic uraemic
syndrome (aHUS), or contribute to the pathology by
mediating tissue injury and inflammation;4 in either
event, it offers a good therapeutic target.
Over the last decade there has been an explosion in com-
plement drug development. Eculizumab, an anti-C5 mono-
clonal antibody (mAb), was a landmark in this work,
approved by the US Food and Drug Administration (FDA)
Abbreviations: Abs, absorbance; AP, alternative pathway; BSA, bovine serum albumin; C5b6, stable complex of C5b and C6; C5,
complement component 5; C6, complement component 6; CI, cocktail of protease inhibitors; CP, classical pathway; EAMG, ex-
perimental autoimmune myasthenia gravis; ELISA, enzyme-linked immunosorbent assay; HBS, HEPES-buffered saline; mAb,
monoclonal antibody; MAC, membrane attack complex; NE, neutrophil elastase; PBS, phosphate-buffered saline; RT, room tem-
perature; ShEA, antibody-sensitized sheep erythrocytes; WB, Western blot
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in 2007 for use in PNH,9–11 years later for aHUS12 and
recently for myasthenia gravis (MG) (news.alexionpharma.-
com/press-release/product-news/fda-approves-soliris-eculizu-
mab-treatment-patients-generalized-myasthenia). Eculizumab
rapidly became the standard treatment for these two ultra-
rare complement-driven diseases (PNH, aHUS). A host of
new agents are in development, targeting the cascade at dif-
ferent stages.13–15 A recent review listed 34 drugs in the
pipeline, many targeting C3 and C5 convertases and the ter-
minal pathway.14 C5 occupies a central position in the com-
plement cascade; the C5 convertase cleaves C5 into C5a and
C5b, the latter essential for assembly of the membrane
attack complex (MAC); inhibition of C5 is therefore an
attractive therapeutic target and the focus of several drugs
in development.15,16 Eculizumab prevents cleavage of C5 by
the C5 convertase, blocking generation of the two most
inflammatory products of the complement cascade; C5a
anaphylatoxin and MAC. The risk of blocking C5 is rela-
tively low; the sole iatrogenic impact of treatment with Ecu-
lizumab is an increased risk of Neisserial infections, resolved
by vaccination before treatment and prophylactic use of
antibiotics.
Despite abundant interest in complement drugs, only
three are currently FDA approved; Eculizumab and a
recently approved variant engineered for extended half-
life, Ravalizumab (ALXN1210; https://ascopost.com/News/
59600), and serum-derived C1-Inhibitor marketed as Cin-
ryze or Berinert.14 Eculizumab has changed outlook in
patients with PNH and aHUS, is now in the clinic for
generalized MG, and is in clinical trials for many other
diseases. Although effective in these rare diseases, the cost
of treatment and high dosage are huge disadvantages for
extending use to more common diseases. For example,
the annual cost of Eculizumab treatment of a PNH
patient is £340 000 in the UK, and the antibody must be
administered bi-weekly by intravenous infusion (900 mg/
dose).4 There are many agents in development that target
C5, for example, SKY59 (RO7112689) an anti-C5 mAb
now in phase II clinical trials. This mAb incorporates a
pH-dependent recycling technology that increases half-life
and decreases dose required for efficient C5 inhibition.17
The modified form of Eculizumab, ALXN1210, uses a
similar pH switch technology to increase recycling effi-
ciency and drug half-life.18,19 Unlike Eculizumab,
RO7112689 also binds C5b6, the intermediate product of
MAC formation, and so inhibits reactive lysis.20
RO7112689 and Eculizumab were used in this study for
comparison with the novel in-house mAb.
We describe novel anti-C5 mAb that, like Eculizumab,
are efficient inhibitors of complement, but unlike Eculi-
zumab, inhibit efficiently across species, including human,
rabbit, rat (clones: 4G2 and 7D4) and weakly guinea pig
and mouse (7D4). The species cross-reactivity of these
mAb makes them powerful tools for proof-of-concept
animal studies. To our knowledge, this is the first report
of cross-species blocking anti-C5 mAb. One of these mAb
was shown to efficiently inhibit complement in vivo in
rats and to prevent disease in a rat model of MG (passive
transfer experimental autoimmune MG; EAMG). Surface
plasmon resonance (SPR) analysis of selected mAb
demonstrated strong and stable binding to both human
and rat C5, making these antibodies very strong candi-
dates for tool therapeutics.
Materials and methods
All chemicals, except where otherwise stated, were
obtained from either Fisher Scientific UK (Loughborough,
UK) or Sigma Aldrich (Gillingham, UK) and were of ana-
lytical grade. All tissue culture reagents and plastics were
from Invitrogen Life Technologies (Paisley, UK). Sheep
and guinea pig erythrocytes in Alsever’s solution were
from TCS Biosciences (Claydon, UK). Eculizumab was
kindly donated by Prof. David Kanavagh (Newcastle
University, UK), and RO7112689 by Roche Diagnostics
(Basel, Switzerland).
Human and animal sera were prepared in house from
freshly collected blood. For human, rabbit, rat and guinea
pig, blood was clotted at room temperature for 1 hr, and
then placed on ice for 2 hr for clot retraction before cen-
trifugation and harvesting of serum. For mouse, blood
was placed on ice immediately after harvest and clotted
for 2 hr on ice before serum harvest. Sera were stored in
aliquots at 80° and not subjected to freeze–thaw cycles.
Generation of anti-C5 mAb
Mouse mAb to C5 were generated by immunization of
C6-deficient mice (bred in house) with C5b6 using stan-
dard schedules.21 C5b6 was used as immunogen to
increase the likelihood of obtaining function-blocking
mAb. C6-deficient mice were derived from a spontaneous
C6-deficient mouse,22 back-crossed eight generations onto
C57BL/6. C5b6 was prepared in house by incubating C5
and C6 with a fluid-phase convertase comprising cobra
venom factor and activated factor B; the complex was
then purified by gel filtration. Immunized mice were
screened for antibody responses by enzyme-linked
immunosorbent assay (ELISA), mice with the highest titre
response were selected and re-boosted before killing and
harvesting of spleens. Plasma cells were harvested, fused
with SP2 myeloma and aliquots were placed in 96-well
plates. Positive hybridomas were selected by direct ELISA
on immobilized C5b6 and by haemolysis assay for block-
ing activity as described below. C5b6-positive comple-
ment inhibitory mAb-secreting clones were sub-cloned by
limiting dilution to monoclonality. Mouse mAb were iso-
typed using IsoStrips (# 11493027001; Roche). Over mul-
tiple fusions, approximately 864 000 hybridoma clones
were screened, 139 antibodies were selected from ELISA,
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12 were confirmed to be inhibitory, and three of these,
4G2, 7D4 and 10B6, were chosen for full characterization.
Haemolytic assays
The inhibitory activity of mAb in human and animal
sera was investigated by classical pathway (CP; CH50)
haemolysis assay using antibody-sensitized sheep ery-
throcytes (ShEA) or alternative pathway (AP; AH50)
assays using rabbit erythrocytes (RabE); animal blood
was from TCS Bioscience and anti-ShE antiserum
(#ORLC25, Siemens Amboceptor) was from Cruinn
Diagnostics (Dublin, UK). ShEA were suspended in
HEPES-buffered saline (HBS) containing Ca2+ and
Mg2+ at 2% (vol : vol), RabE in HBS containing 5 mM
EGTA and 3 mM MgCl2.
23 For measurement of CP
activity in male mouse serum, ShEA were additionally
incubated with mouse anti-rabbit IgG at 25 lg/ml
(#3123; Invitrogen) for 30 min at 37° before washing
in HBS. A serial dilution series of each test mAb (100–
0 lg/ml; 50 ll/well) was prepared in HBS and ali-
quoted in duplicate into a 96-well round-bottomed
plate at 50 ll/well, then serum and 2% ShEA (50 ll/
well of each) added. Serum dilutions for each species
were selected in preliminary experiments to give near-
complete haemolysis in the CP assay in the absence of
test mAb: normal human serum, 25%; normal male
mouse serum, 25% (using the double-sensitized cells as
described above), normal rat serum, 25%; normal gui-
nea pig serum, 25%; normal rabbit serum, 25%. Plates
were incubated at 37° for 30 min, centrifuged and hae-
moglobin in the supernatant was measured by absor-
bance at 405 nm. Percentage lysis was calculated
according to: % Lysis = Absorbance (Abs) sam-
ple – Abs background)/(Abs max  Abs back-
ground) 9 100%. GRAPHPAD PRISM was used for data
analysis. Hybridoma supernatants were screened for
blocking mAb using the same assay but with neat tissue
culture supernatant in place of the purified mAb. C5a
generation in CP haemolysis assay supernatants was
measured using an ELISA kit (# HK349-02; Hycult Bio-
tech, Uden, the Netherlands).
Characterization of novel mAb by ELISA
Direct ELISA and sandwich assay were used to test
whether the new mAb bound C5, C6 or C5b6. Sandwich
ELISA were used to confirm C5 binders to eliminate
issues around denaturation and demonstrate separate epi-
topes for test mAb to RO7112689 used as capture. Stan-
dard curves were generated using in-house proteins; C5,
C5b6 and C6 purified as previously described20,23.
In the direct ELISA, Maxisorp (Nunc, Loughborough,
UK) 96-well plates were coated with C5, C5b6 or C6
(05 lg/ml in bicarbonate buffer, pH 96) at 4°
overnight; wells were blocked [1 hr at 37° with 2%
bovine serum albumin (BSA) in phosphate-buffered
saline (PBS)], washed in PBS containing 005% Tween-
20 (PBS-T). Dilutions of purified mAb, 1000–0 ng/ml
(stock concentrations of all proteins used established
using the BCA assay) in 02% BSA-PBS, were added in
triplicate to wells coated with each of the three antigens
and incubated for 1 hr at 37°. Wells were washed with
PBS-T then incubated (1 hr, 37°) with secondary anti-
body (donkey anti-mouse-horseradish peroxidase
(HRP); Jackson ImmunoResearch, Ely, UK) for 1 hr at
37°.
In the sandwich ELISA, Maxisorp plates were coated
with RO7112689 or Eculizumab (1 lg/ml in bicarbon-
ate buffer, pH 96) at 4° overnight; wells were blocked
(1 hr at 37° with 2% BSA-PBS) and washed in PBS-T.
Standard curves of in-house purified proteins; C5,
C5b6 and C6 diluted in 02% BSA-PBS, were added in
triplicate and incubated for 1 hr at 37°. Wells were
washed with PBS-T then incubated (1 hr, 37°) with in-
house mAb anti-C5 (1 in 1000 dilution in PBS-T), fol-
lowed after washing with HRP-labelled anti-mouse IgG
as above.
After washing, plates were developed using O-
phenylenediamine dihydrochloride (OPD, SIGMAFASTTM;
Sigma-Aldrich) and absorbance (492 nm) was measured.
GRAPHPAD PRISM was used for data analysis. Assays detec-
tion limits, working ranges and assay performance were
determined as described.24
Characterization of mAb by Western blot
C5, C5b6 and C6 (in house; 1 lg) were placed in sepa-
rate wells and resolved on 4–20% sodium dodecyl sul-
phate–polyacrylamide gel electrophoresis gels (#4561093;
Biorad, Hemel Hempstead, UK) under reducing and
non-reducing conditions, then electrophoretically trans-
ferred onto 045-lm nitrocellulose membrane (GE
Healthcare, Amersham, UK). After transfer, non-specific
sites on the membrane were blocked with 3% BSA in
PBS-T. After washing in PBS-T, membrane strips were
incubated overnight at 4° with individual test mAb
(clone 4G2, 7D4, 10B6; each at 1 lg/ml in 3% BSA
PBS-T) or controls RO7112689 (1 lg/ml) or polyclonal
(goat) anti-human C5 (CompTech, Tyler, TX; A220;
2 lg/ml). After washing, bound test mAb were detected
by incubation with donkey anti-mouse IgG-HRP (715-
035-150; Jackson ImmunoResearch), RO7112689 with
donkey anti-human IgG-HRP (709-036-149; Jackson
ImmunoResearch) and polyclonal anti-C5 with rabbit
anti-goat IgG HRP conjugate (305-035-045; Jackson
ImmunoResearch) at 1 : 5000 in PBS-T. After
washing, the blot was developed with enhanced chemi-
luminescence (GE Healthcare) and visualized by
autoradiography.
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Testing impact of mAb on atypical cleavage of C5 by
neutrophil elastase
C5 was mixed with test mAb at 59 molar excess in HBS,
then incubated for 15 min at room temperature. Neu-
trophil elastase (NE, # 16-14-051200; Athens Research,
Athens, GA) was added at 420 nM final concentration,
incubated for 30 min at 37° in a shaking water bath, and
the reaction was stopped by addition of 61 nM protease
cocktail inhibitors (CI, #P8340; Sigma Aldrich). C5 cleav-
age was determined by measuring generation of C5a,
detected by WB and by ELISA (# HK349-02; Hycult Bio-
tech). For WB, samples were diluted 1 in 2 in HBS, sepa-
rated and transferred as above. Blots were probed with
anti-C5a mAb (#HM2079; Hycult Biotech), detected
using donkey anti-mouse IgG-HRP (Jackson ImmunoRe-
search, 715-035-150). Positive controls included intact C5
(in house), C5a (Comptech), NE and CI diluted in HBS.
SPR analysis to determine test mAb binding affinity to
human and rat C5
The human C5 mAb binding analyses were carried out
on a Biacore S200, whereas rat C5 mAb binding was
tested using a T200 instrument (GE Healthcare); in both,
a Mouse Antibody Capture kit (# BR-1008-38; GE
Healthcare) was used to immobilize capture antibody on
a CM5 sensor chip (#29-1496-03; GE Healthcare) at
RU = 500 (for human C5 testing) or 400 (for Rat C5
analysis). Test mAb were flowed to saturate the surface,
then C5 proteins (human or rat) in HEPES-buffered sal-
ine (10 mM HEPES, pH 74, 150 mM NaCl, 0005% sur-
factant P20) flowed over the immobilized mAb. For
kinetic analysis, the flow rate was maintained at 30 ll/
min, and data were collected at 25°. Data from a refer-
ence cell were subtracted to control for bulk refractive
index changes. The Rmax was kept low and the flow rate
high to eliminate mass transfer. All reagents used were of
high purity, polished by size exclusion chromatography
immediately before use to ensure removal of any aggre-
gates. Data were evaluated using the software appropriate
to the instrument (BIACORE EVALUATION Software, GE
Healthcare).
Passive transfer EAMG in rats
To test in vivo effects and therapeutic efficacy of test
mAb, Wistar Han IGS rats (100–150 g) were obtained
from Charles River Laboratories (Edinburgh, UK) and
allowed to acclimatize for 1 week before disease induction
by intraperitoneal administration of anti-Acetylcholine
receptor (AChR) mAb35 at 1 mg/kg in PBS as described
previously.25 mAb35 binds the main immunogenic region
of AChR, activating complement and damaging the neu-
romuscular junction endplates, causing severe muscle
weakness. Animals were assessed hourly post-disease initi-
ation as described previously.25,26 mAb35-injected rats
were split into two groups: Group one (n = 4) was trea-
ted with test mAb at 40 mg/kg dose (selected dose deter-
mined in a pilot study) subcutaneously at time zero, with
a second subcutaneous dosage of 13 mg/kg at 24 hr. The
second group (n = 3) received an irrelevant isotype con-
trol antibody at the same times, routes and doses. All ani-
mals were killed at 40 hr post-induction, blood was taken
for serum assays, soleus muscles were harvested and fro-
zen in OCT mounting medium for sectioning as
described previously.25,26 Sections were fixed in ice-cold
acetone for 15 min at 80° and then blocked for 30 min
in 10% horse serum/2% BSA. After washing in PBS, sec-
tions were stained overnight at 4° with primary antibod-
ies, C3/30 anti-C3b/iC3b mAb (in house) at 10 lg/ml,
and rabbit anti-rat C9/MAC polyclonal IgG (in house) at
50 lg/ml, both in the block buffer. Anti-C3b/iC3b sec-
tions were washed and incubated for 15 min at room
temperature with amplifier antibody goat anti-mouse
(VectaFluor DyLight 488, # DK-2488; Vector Labs, Peter-
borough, UK). After washing, secondary antibody, horse
anti-goat IgG – Alexa Fluor 488 (DyLight 488, # DK-
2488) for C3b/iC3b or goat anti-rabbit-FITC (#45002;
Oxford Biomedical Research, Rochester Hills, MI, USA)
for anti-C9/MAC were added as appropriate, together
with a-bungarotoxin-TRITC (BtX) (labels AChR; Boitum,
# 00012) at 05% and Hoechst stain 1 : 10 000 (# 62249;
ThermoFisher), then incubated 40 min at room tempera-
ture in the dark. Sections were washed in PBS and
mounted in VectorShield Vibrance (#H-1700-2; Vector
Labs) before analysis using an Apotome fluorescence
microscope (Zeiss Apotome Axio Observer microscope,
Carl Zeiss Microscopy, Cambridge, UK). Ten fields were
captured from comparable regions of muscle in each
sample at the same exposure and magnification (940)
and the number of BuTx-reactive endplates in each sec-
tion was measured using density slicing in an image anal-
ysis system (IMAGEJ, University of Wisconsin-Maddison,
Maddison, WI, USA). For co-localization of complement
activation products, sections were additionally imaged on
a Zeiss confocal microscope (Zeiss LSM800 confocal laser
scanning microscope).
Results
Cross-species complement inhibition by mAb in
haemolysis assays
Hybridoma clones were initially selected for further char-
acterization based upon the capacity of clone super-
natants to cause inhibition of CP haemolysis of ShEA by
human serum; three of the selected monoclonal clones;
4G2 (IgG2b, K), 7D4 (IgG2b, K), 10B6 (IgG1, K), were
expanded for further characterization, secreted mAb
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purified and further tested in haemolysis assays. As
expected, each of the selected mAb efficiently inhibited
normal human serum-induced CP haemolysis, with clone
10B6 showing equivalent dose–response performance to
the benchmark mAb RO7112689 and Eculizumab
(Fig. 1a). When the impact of the mAb on CP haemolysis
induced by other species sera was tested, mAb 4G2 and
7D4 efficiently inhibited haemolysis mediated by either
rat or rabbit serum (Fig. 1b,c) and weakly inhibited
haemolysis by guinea pig and mouse sera (Fig. 1d,e). In
contrast, neither the new mAb 10B6 nor Eculizumab
inhibited any of these non-human sera, although
RO7112689 inhibited mouse, guinea pig and rabbit but
not rat serum-induced haemolysis. The calculated 50%
complement inhibitory doses of all mAb are shown
(Fig. 1f); guinea pig serum is not included in this sum-
mary because levels of inhibition did not reach 50% for
any of the mAb. The novel mAb 10B6, 4G2 and 7D4 also
showed efficient inhibition of AP lysis in human serum
(Fig. 1g), whereas 4G2 and 7D4 efficiently inhibited rat
AP (Fig. 1h). C5a release was inhibited by the novel mAb
at the same levels as MAC generation (66 nM) in the
human CP assay (Fig. 1i).
Binding of mAb to C5 and C5b6
The direct ELISA showed that all the selected new mAb
recognized C5 and C5b6 and none recognized C6
(Fig. 2a–c). In a sandwich ELISA with RO7112689 (anti-
C5b) as capture and 4G2 mAb as detection, C5 and
C5b6, but not C6, were detected; demonstrating that
mAb 4G2 and RO7112689 antibodies recognized different
epitopes on C5 and C5b in the C5b6 complex (Fig. 2d).
To confirm which chains of C5 the new mAb bound,
we performed Western blotting on purified C5. The blots
demonstrated that mAb 4G2 and 7D4 bound the a-chain
in C5; of note, although 7D4 recognized both residual
a-chain and the a0-chain in C5b6, 4G2 only bound
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Figure 1. Functional assays to determine whether monoclonal antibodies (mAb) 4G2, 7D4 and 10B6 inhibit complement in different species.
(a–e) Classical pathway haemolysis (CH50). Sera tested were human (a), rat (b), rabbit (c), guinea pig (d) and mouse (e). Commercial mAb
RO7112689 and Eculizumab were used as comparators. (f) Calculation of 50% inhibitory dose showed that human C5 inhibition by mAb 10B6
was equivalent to the two comparator mAb, RO7112689 and Eculizumab, and that 4G2 and 7D4 strongly inhibited rat C5. (g, h) Alternative
pathway (AP) haemolysis (AH50) assay using human (g) and rat (h) serum; all tested mAb inhibited AP in human serum, while 4G2 and 7D4
inhibited rat AP. (i) Inhibition of C5a generation by the novel mAb in a classical pathway assay with human serum; all three mAb efficiently
inhibited C5a generation in a dose-dependent manner. All experiments were repeated three times with the same results. The error bars are stan-
dard errors of triplicates. The dashed lines correspond to the comparator mAb.
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residual intact a-chain (Fig. 3a,b). 10B6 recognized the b-
chain of C5 (Fig. 3c); RO712689 also recognized the b-
chain (Fig. 3d), whereas Eculizumab is known to bind
the macroglobulin 7 domain in the a-chain.27 Polyclonal
anti-C5 recognized both C5 a- and b-chains (not shown).
To test whether the novel anti-C5 mAb recognized epi-
topes distinct from the commercial mAb, sandwich ELISA
were developed using RO7112689 or Eculizumab as the
capture mAb. With RO7112689 as capture, both the C5a-
specific mAb (7D4 and 4G2) bound strongly but the
C5b-specific 10B6 did not bind (Fig. 2e). With Eculizu-
mab (anti-C5a) capture, the b-chain-specific mAb 10B6
bound most strongly whereas the anti-C5a mAb bound
weakly (4G2) or not at all (7D4), suggesting that they
competed for similar epitopes (Fig 2f).
SPR analysis on immobilized antibody with human C5
flowed over (Fig. 4a–c) showed binding between human
C5 and each of the novel mAb. The mAb 10B6 and 7D4,
showed strong binding to human C5 in SPR analyses
(KD = 4105 9 1010, 1264 9 109, respectively) with
negligible off rates, suggesting that 10B6 and 7D4, respec-
tively, targeting the b and a chains of C5, might be
promising candidates for therapeutics. Binding of human
C5 to 4G2 was relatively weak (KD = 1389 9 108;
Fig. 4a); in contrast, binding of rat C5 to 4G2 was strong
and stable (KD = 4872 9 109). The relatively slow off
rate of rat C5 from mAb 4G2 suggested that this mAb
offered promise for use in vivo in rats because 4G2 and
C5 will form a stable complex, delivering prolonged inhi-
bition. Technical issues precluded the analysis by SPR of
7D4 binding to rat C5.
Induction of EAMG in rats and effect of mAb 4G2 on
clinical disease and pathology
Rats given mAb35 at 1 mg/kg intraperitoneally and an
irrelevant isotype control mAb subcutaneously began to
lose weight and show signs of hind limb weakness
(Fig. 5a).25 Clinical symptoms, comprising limp tails,
piloerection, hind limb weakness and reduced grip
strength, were detectable in isotype control treated ani-
mals by 18 hr post-induction, and all exhibited severe
disease with hind limb weakness and/or partial paralysis,
reaching clinical score 4 on a standardized scale (0, no
disease; 1, reduced grip strength in front legs (can grip
cage lid but cannot lift) and floppy tail; 2, loss of grip in
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Figure 2. Direct and sandwich ELISA for char-
acterization of new monoclonal antibodies
(mAb). In direct ELISA, plates were coated with
human C5 (a), C5b6 (b) or C6 (c). All new mAb
detected C5 and C5b6 complex, but not C6. In a
sandwich ELISA with RO7112689 as the capture
and in house 4G2 mAb as detection (d), both C5
and C5b6, but not C6 were detected showing
that mAb 4G2 and RO7112689 antibodies rec-
ognized different epitopes in C5. Sandwich
ELISA comparing RO7112689 (e; anti-C5b) and
Eculizumab (f; anti-C5a) as capture mAb
showed that both the C5a-specific mAb (7D4
and 4G2) bound strongly to RO7112689-cap-
tured C5 but the C5b-specific 10B6 did not bind
(e); the b-chain-specific mAb 10B6 bound most
strongly to Eculizumab-captured C5 whereas the
anti-C5a mAb bound weakly (4G2) or not at all
(7D4), suggesting that they competed for similar
epitopes (f). All experiments were repeated three
times with the same results. The error bars are
standard errors of triplicates.
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front legs; 3, loss of grip and hind limb weakness and
wasting; 4, loss of grip and hind limb paralysis; 5, mori-
bund) by end point. In contrast, animals given mAb 4G2
subcutaneously at the time of disease induction continued
to gain weight over the time course of the experiment
and did not develop detectable weakness or other clinical
manifestations for the duration of the experiment
(Fig. 5b). Animals were killed using a Schedule 1 method
when weight loss was equal to or exceeded 20% of origi-
nal bodyweight, or when clinical score reached 4. CP hae-
molytic activity in serum was essentially absent at 2 hr
post-induction in 4G2-treated animals but at later time-
points, residual haemolytic activity of approximately 35%
of controls was detected (Fig. 5c), probably due to the
high sensitivity of the haemolytic assay for residual C5.20
As expected, serum from the untreated control animals
retained full haemolytic activity across the time course.
Soleus muscles were harvested at time of death (40 hr),
sections (10 lm) were prepared, fixed in acetone and
endplates were identified by staining AChR with a-Bun-
garotoxin-TRITC. Receptor numbers were quantified
across 10 different representative fields in an automated
imaging system and analysed using IMAGEJ software. The
number of endplates in isotype control animals was
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Figure 3. Western blot (WB) using novel
monoclonal antibodies (mAb; 4G2, 7D4, 10B6)
in comparison with anti-C5 mAb RO7112689.
Proteins; human C5, C5b6 and C6 (1 lg) were
resolved on 4–20% PAGE gels under non-re-
ducing (NR) and reducing (R; 5% b-mercap-
toethanol) conditions. Blots were probed with
mAb 4G2 (a), 7D4 (b), 10B6 (c), RO7112689
(d). All mAb detected intact C5 and C5b but
not C6 in the C5b6 complex. The mAb 4G2
and 7D4 bound the C5a chain, while mAb
10B6 and RO7112689 bound the C5b chain.
All mAb except 4G2 detected C5b6 in reducing
conditions. In-house produced C5b6 probed
with RO7112689 showed trace contaminating
human antibody bands from the immunoaffin-
ity purification process detected by the
anti-human IgG secondary. Results are repre-
sentative of multiple analyses.
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significantly decreased compared with mAb 4G2-treated
animals (approximately twofold less; Fig. 5d); endplate
numbers in the 4G2 group were not significantly different
from numbers in naive animals (data not shown). Resid-
ual endplates were frequently fragmented in isotype con-
trol animals, whereas most endplates in 4G2-treated
animals displayed the typical continuous, linear character.
The a-Bungarotoxin fluorescence intensity was signifi-
cantly higher in the 4G2-treated animals (P = 0002,
Fig. 5e). Whereas C3 fragment staining intensity was sim-
ilar between the groups, C9/MAC staining was reduced
more than threefold in the 4G2-treated group
(P < 00001; Fig. 5f,g). Confocal analysis and co-localiza-
tion of C3b/iC3b and C9/MAC deposition at the endplate
demonstrated strong and specific deposition of C3b/iC3b
and MAC at the endplate in isotype control animals at
40 hr (Fig. 5h), whereas in 4G2-treated animals, C3b/
iC3b was deposited to a similar degree at endplates but
C9/MAC deposition was weak or absent (Fig. 5i).
mAb 4G2 but not mAb 7D4 and 10B6 block atypical
cleavage of C5 by neutrophil elastase
To test whether any of the new mAb inhibited atypical
cleavage of C5, C5 was incubated with NE with or with-
out an excess of each of the mAb; C5a generation,
detected by Western blot, was used as an index of C5
cleavage. Although C5 cleavage products were present in
all cases, complete inhibition of NE-mediated C5a genera-
tion was observed when mAb 4G2 was used, whereas
10B6 and 7D4 caused a partial inhibition of C5a genera-
tion compared with the no-mAb control (Fig. 6a). When
tested in this assay, RO7112689 completely inhibited C5a
generation while Eculizumab had no effect on C5a pro-
duction; an irrelevant non-blocking anti-C5 (3D3) also
did not inhibit C5a generation (Fig. 6a). Densitometric
analysis of the C5a band showed a ~95% inhibition of
C5a generation by 4G2 and RO7112689, 40% by 10B6
and 20% by 7D4 compared with cleavage in the absence
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Figure 4. Binding kinetics of the novel monoclonal antibodies (mAb) to human and rat C5. Each mAb (4G2, 7D4, 10B6) was immobilized on
the mouse IgG capture sensor chip (GE Healthcare) at approximately 60 RU (insets in each). C5 was flowed in HEPES-buffered saline (HBS) at
66 to 8 nM for human and 33 to 4 nM for rat C5 and interactions with the immobilized mAb were analysed. Sensorgrams were collected and KDs
were calculated using the Langmuir 1 : 1 binding model with RI values set to zero. Representative sensorgrams are shown with raw data in black
lines and fitted data in grey (n = 3). (a) mAb 4G2 binding human C5; (b) mAb 7D4 binding human C5; (c) mAb 10B6 binding human C5; (d)
mAb 4G2 binding rat C5; (e) summary table of KDs from the aggregate studies.
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of antibody (Fig. 6b). These data were confirmed by
ELISA; when compared with the amount of C5a gener-
ated by NE in the absence of antibody (670 ng/ml in the
assay; 100%), the amount of C5a generated was reduced
to ~4% by inclusion of 4G2 or RO7112689; 73% by 7D4;
59% by 10B6; Eculizumab did not inhibit C5 cleavage in
this assay (Fig. 6c).
Discussion
Twelve years ago, the first complement inhibitor, Eculizu-
mab was approved for use in therapy of PNH. The dis-
covery of Eculizumab and its dramatic success in this
ultra-rare disease catalysed Pharma interest in anti-com-
plement drugs, resulting in many new agents targeting
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Figure 5. Therapeutic effect of monoclonal antibody (mAb) 4G2 in experimental autoimmune myasthenia gravis (EAMG). EAMG was induced
in rats and weight loss (a) and clinical score (b) were monitored. Control animals (EAMG) rapidly developed weight loss and muscle weakness,
reaching clinical scores of four or five and all were killed at 40 hr. The mAb 4G2-treated animals were protected from disease and weight loss; all
were killed at 40 hr. Serum lytic activity was measured at multiple time-points (0, 2, 18, 24 and 40 hr) in each animal (c). Results are means of
determinations from four 4G2-treated and three isotype control-treated EAMG animals and vertical bars represent SD. Soleus muscles were har-
vested at time of killing and snap frozen in OCT. Sections (10 lm) were stained for AChR with TRITC-conjugated a-BuTX and visualized by
Zeiss Apotome microscope; AChR-positive endplates were counted in 10 fields from each animal using IMAGEJ software (d). Mean fluorescence
intensity of BuTx staining in the sections (mean pixel intensity values from IMAGEJ) was significantly higher in 4G2-treated animals compared
with controls (e; P = 0002). Mean fluorescence intensity of C3b/iC3b was not significantly (NS) different between the two groups (f), while C9/
MAC staining was markedly reduced in 4G2-treated animals (g; P < 00001). Statistical significance was obtained by t-test and P < 005 was con-
sidered as significant. Tissue sections from isotype control (h) or 4G2-treated (i) animals were double-stained for AChR together with anti-C3b/
iC3b (top panel) or C9/MAC (bottom panel) and imaged on a Zeiss confocal microscope. The scale bar is shown in the first plate; all images
were captured at identical magnification.
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different complement pathways being developed.4,14,16
Eculizumab is an effective terminal pathway blocker;
however, for several years its use has been restricted to
only two ultra-rare diseases, PNH and aHUS, and latterly
approved for MG treatment. In recent years, pathological
roles of complement in more common conditions like
MG, age-related macular degeneration and neurodegener-
ation have been demonstrated, building a case for the
broader use of anti-complement drugs in the clinic.27–29
Cost and convenience are limiting factors in broadening
anti-complement drug use; current cost and dosing
schedules for Eculizumab are incompatible with use in
the treatment of common, chronic diseases. It is therefore
imperative that new agents and approaches are brought
to bear on C5 inhibition; increasing drug half-life (and
hence reducing dose) has been a first approach both with
the Eculizumab-derived ALXN1210 and the competitor
mAb RO7112689, but other approaches, including small
molecule inhibitors of C5,30 are in train. A second limit-
ing factor is that the currently available agents are
human-specific, restricting proof-of-concept of efficacy of
C5 inhibition in rodent disease models. The mAb BB51
has been widely used in mouse models,31,32 and a single
report described a blocking anti-C5 mAb that was not
further used,33 apart from these, no anti-C5 mAb inhibit-
ing in other animal species have been described.
Here we immunized C6-deficient mice with C5b6 to
develop functionally optimal mAb, selecting from the
outset for function-blocking activity. Of 864 000 hybri-
doma clones screened, 139 were ELISA-positive, 12 of
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Figure 6. Impact of anti-C5 monoclonal antibodies (mAb) on cleavage of C5 by neutrophil elastase. (a) Western blot of atypical cleavage of C5
by neutrophil elastase (NE). C5 was mixed with each mAb at 59 molar excess in HEPES-buffered saline (HBS), NE was added at 420 nM, incu-
bated and the reaction was stopped by addition of protease inhibitors. Samples (1 lg) were resolved on 4–20% SDS–PAGE gels under reducing
(R) conditions and processed for WB to detect intact or cleaved C5 and C5a using an anti-C5a mAb that also detects native C5a chain (Hycult;
mAb 2942). C5a (115 000 MW), C5a (104 000 MW), CI; proteases cocktail inhibitors, Ecul.; Eculizumab, RO; RO7112689, 3D3; irrelevant non-
blocking anti-C5 mAb. Note that numerous unidentified C5 cleavage products are present in all NE-treated samples. (b) Densitometry analysis of
the C5a band using IMAGEJ (expressed as % relative to the C5a generation in the absence of antibody; 100%) confirmed that mAb 4G2 and com-
mercial mAb RO7112689 efficiently inhibited generation of C5a. (c) measurement of C5a generation by ELISA confirmed that mAb 4G2 and
RO7112689 inhibited C5a generation while other mAb inhibited weakly. ELISA results are presented as percentage relative to C5a generation in
the absence of any mAb (set as 100%; measured as 670 ng/ml in the ELISA). Results are representative of three independent experiments. The
error bars are standard errors of triplicates.
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these were inhibitory, and three inhibitory clones were
selected for full characterization. All mAb selected based
on blocking activity bound native C5 and C5b6 (the
immunogen), but not C6, in ELISA. Three of these
human C5-blocking mAb were selected for further char-
acterization; testing for inhibition in other species showed
that two of the mAb, 7D4 and 4G2 (both against C5a
chain), inhibited C5 in rat, rabbit, guinea pig and mouse
sera, whereas 10B6 (against C5b chain) was human-spe-
cific. RO7112689 bound the C5b chain, as reported previ-
ously,20 and was a weak inhibitor of guinea pig and
mouse C5 (Fig. 3), whereas Eculizumab bound C5a and
is human-specific.34 The critical residue in the Eculizu-
mab binding site that dictates human specificity is
Trp917, which is replaced by Ser in other species, includ-
ing non-human primates, rat, mouse, rabbit, guinea pig,
sheep, pig and horse as reported,34,35 and from our data
base search (www.ncbi.nlm.nih.gov/protein). The fact that
the two blocking anti-C5a mAb 7D4 and 4G2 work
across species suggests that they bind an epitope distinct
from that in C5a bound by Eculizumab; this is supported
by the demonstration that these mAb bind C5b6 (the
immunogen) in the direct ELISA while Eculizumab does
not. The mAb 4G2 detected C5 captured on Eculizumab
in a sandwich assay, confirming that the epitopes are dis-
tinct; however, 7D4 did not bind in this assay, indicating
that its epitope overlaps that of Eculizumab. When
RO7112689 (C5b-specific) was used as capture in the
assay, both the C5a-binding mAb detected the bound C5
as anticipated; in contrast, the C5b-specific mAb 10B6
gave no signal, demonstrating that its epitope was masked
by the capture mAb. Of note, RO7112689, like 10B6, also
binds C5b6. These data indicate that the epitopes for
these two mAb are overlapping; the fact that RO7112689
inhibits across species while 10B6 is human-specific sug-
gests that the epitopes are non-identical. It is clear from
the above findings, and from published work comparing
tick-derived C5 inhibitors with Eculizumab, that there are
numerous sites on C5 where binding of an inhibitor can
effectively block function.36 This supports the suggestion
that these diverse inhibitors act as conformation locks,
preventing a structural ‘priming’ event that is necessary
for cleavage of C5 by the convertase.
The mAb were also tested for their capacity to block
the atypical cleavage of C5 by NE, a process that has
been implicated in the generation of C5a and MAC at
inflammatory sites such as in the rheumatoid joint and
cystic fibrosis lung;37–39 mAb that inhibited this cleavage
might therefore have additional value as therapeutics.
The mAb 4G2 strongly inhibited NE-mediated C5 cleav-
age and C5a generation in vitro, whereas the other two
novel mAb weakly inhibited atypical C5 cleavage
(Fig. 6). Eculizumab did not inhibit C5 cleavage by NE
but RO7112689 effectively blocked generation of C5a by
NE (Fig. 6c).
SPR analysis (Biacore) showed strong and stable bind-
ing of 7D4 and 10B6 to human C5 with dissociation rates
and calculated affinities comparable to RO711268917
(Fig. 4). In contrast, 4G2 binding to human C5 was
much weaker – but this mAb bound rat C5 much more
strongly than human (KD 4872 9 109 for rat and
1389 9 108 for human) and with a slow off-rate; these
binding data support the functional assays where 4G2 was
a more potent inhibitor of rat C5 than human (Fig. 1).
The 4G2 mAb was tested in vivo as a prophylactic therapy
in a model of MG, previously demonstrated to be depen-
dent on MAC assembly in man and rodents and sup-
pressed by terminal pathway deficiencies or
inhibition.24,26 Although control animals developed severe
muscle weakness and weight loss, mAb 4G2-treated rats
were protected from disease and weight loss (Fig. 5a,b).
Endplates in controls were reduced in number, frag-
mented and richly decorated with C3b/iC3b and C9/
MAC, whereas in 4G2-treated animals endplates were
preserved in number and integrity; although endplates
were strongly C3b/iC3b-positive in these animals, C9/
MAC deposition was markedly reduced or absent (Fig. 6).
Although mAb 4G2 proved to be an efficient blocker of
EAMG, assays of serum haemolytic activity showed ~35%
residual lysis after the 2 hr time-point in 4G2-treated ani-
mals. We have previously demonstrated that as little as
2 ng/ml C5 added back to undiluted C5-depleted serum
is sufficient to cause measurable lysis, and 50% lysis in
the assay was attained at 2 lg/ml C5 added back.20 These
findings illustrate the exquisite sensitivity of the haemoly-
tic assay and show that it is not a good predictor of effi-
cacy of C5 inhibition in disease. We have not yet tested
this mAb for amelioration of established disease in the
EAMG model, which would be difficult given the acute
nature of the model, or in more chronic disease models;
such studies are planned in the future.
The novel mAb described here are efficient blockers of
human C5, with binding sites and other properties dis-
tinct from existing anti-C5 mAb. All three mAb bind
C5b6, used as the immunogen, and block reactive lysis, a
property absent from Eculizumab that may provide a
therapeutic advantage. Notably, two of the mAb inhibit
C5 in common laboratory animal species, raising the pro-
spect of their use as tools in proof-of-concept studies,
illustrated here using EAMG as an example. One of the
new mAb was a strong inhibitor of elastase-mediated C5
cleavage, raising the possibility of testing the impact of
blocking atypical C5 cleavage in inflammatory diseases
where neutrophil activation predominates in rodents or
man.
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